Primary Percutaneous Coronary Interventions Among Acute STEMI Cases: Predictors for No Re¬ Flow
Keywords:
re-flow, ST-segment elevation myocardial infarction, PCI, STEMI, percutaneous coronary intervention.Abstract
Background: no reflow has been recognized as a serious primary percutaneous coronary intervention-associated complication, its incidence is related with poor clinical consequences. The goal of the present research is to evaluate the angiographic and clinical determinants of no-reflow. Methods: The clinical and angiographic characteristics of cases of primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction at the Shaheedul-Mihrab center between January 2015 and September 2016, were retrospectively evaluated. Results: There were 11.5% no-reflow cases. While diabetes, smoking history, sex category, and infarct location did not affect the probability of no-reflow, a history of hypertension and older age did. A higher syntactic score, a greater thrombus burden, and a low primary TIM I flow were all corelated with no re-flow.
Downloads
References
Al-Saad RZ, Shaker AK, Dleikh FS, & Al-Hindy
HA-AM (2020) Is There Any Association
Between Highly Sensitive Creactive Protein
and Dental-status in Ischemic Heart
Diseases? A Comparative Study. Biochemical
& Cellular Archives 20 (2): 6069-6075. URL:
https://www.researchgate.net/profile/Hayder
-Maki/publication/347318185
Al-Shamma YMH, Alkhafaji AAA, & Al-Hindy
HA-A (2022) Caries burden is associated with
serum uric acid and CRP in patients treated
for acute coronary syndrome. HIV Nursing 12
(2): 050-056. DOI:
http://dx.doi.Org/10.31838/hiv23.02.9
Alhaideri AF, Al-Agam A, Alzughaibi M, AlHindy H, & Mousa M (2022)
Hypovitaminosis D is a biological
vulnerability for depressive symptomsin major
depression at the era of COVID-19 outbreak.
Clinical Schizophrenia & Related Psychoses 5
Antoniucci D, Valenti R, Migliorini A, Moschi G,
Bolognese L et al. (2001) Direct infarct artery
stenting without predilation and no-reflow in
patients with acute myocardial infarction.
American heart journal 142 (4): 684-690.
DOI:
https://doi.org/10.1067/mhj.2001.117778
Aung Naing K, Li L, Su Q, & Wu T (2013)
Adenosine and verapamil for no-reflow during
primary percutaneous coronary intervention
in people with acute myocardial infarction.
Cochrane Database Syst Rev (6): Cd009503.
DOI:
https://doi.org/10.1002/14651858.CD0095Q
pub2
Bolognese L, Carrabba N, Parodi G, Santoro
GM, Buonamici P et al. (2004) Impact of
microvascular dysfunction on left ventricular
remodeling and long-term clinical outcome
after primary coronary angioplasty for acute
myocardial infarction. Circulation 109 (9):
-1126. DOI:
https://doi.org/10.1161/0LCIR.0000118496.
A7
Chen Y, Wang C, Yang X, Wang L, Sun Z et al.
(2012) Independent no-reflow predictors in
female patients with ST-elevation acute
myocardial infarction treated with primary
percutaneous coronary intervention. Heart and
vessels 27: 243-249. DOI:
https://doi.org/10.1007/s00380-011-0144-2
De Luca G, Ernst N, Zijlstra F, Van't Hof AW,
Hoorntje JC et al. (2004) Preprocedural TIMI
flow and mortality in patients with acute
myocardial infarction treated by primary
angioplasty. Journal of the American College
of Cardiology 43 (8): 1363-1367. URL:
https://www jacc.org/doi/abs/10.1016/j jacc.
11.042
Fajar JK, Heriansyah T, & Rohman MS (2018)
The predictors of no reflow phenomenon after
percutaneous coronary intervention in
patients with ST elevation myocardial infarction: A meta-analysis. Indian Heart
Journal 70: S406-S418. DOI:
https://doi.org/10.1016/j.ihj.2018.01.032
Galasso G, Schiekofer S, D’Anna C, Gioia GD,
Piccolo R et al. (2014) No-reflow phenomenon:
pathophysiology, diagnosis, prevention, and
treatment. A review of the current literature and
future perspectives. Angiology 65 (3): 180-189.
DOI:
https://doi.org/10.1177/0003319712474336
Ghazi HAA-M, Al-Taee RAM, & Al-Hindy HAAM (2020) Immunophenotypic
characterization of malignant lymphoma in
Iraqi patients using immunohistochemical
CD-marker study. Systematic Reviews in
Pharmacy 11 (11): 412-417. DOI:
http://dx.doi.org/10.31838/srp.2020.lL61
Harrison RW, Aggarwal A, Ou F-s, Klein LW,
Rumsfeld JS et al. (2013) Incidence and outcomes
of no-reflow phenomenon during percutaneous
coronary intervention among patients with acute
myocardial infarction. The American journal of
cardiology 111 (2): 178-184. DOI:
https://doi.Org/10.1016/i.amicard.2012.09.015
Kazaili A, Abdul-Amir Al-Hindy H, Madine J, &
Akhtar R (2021) Nano-scale stiffness and
collagen fibril deterioration: Probing the
cornea following enzymatic degradation using
peakforce-qnm afm. Sensors 21 (5): 1629.
DOI: https://doi.org/10.3390/s21051629
Keeley EC, Boura JA, & Grines CL (2003) Primary
angioplasty versus intravenous thrombolytic
therapy for acute myocardial infarction: a
quantitative review of 23 randomised trials. The
lancet 361 (9351): 13-20. DOI:
https://doi.oig/10.1016/S0140-6736(03)12113-
Kirma C, Izgi A, Dundar C, Tanalp AC, Oduncu
V et al. (2008) Clinical and procedural
predictors of no-reflow phenomenon after
primary percutaneous coronary interventions
Experience at a Single Center. Circulation
Journal 72 (5): 716-721. DOI:
https://doi.org/10.1253/circj.72.716
Kloner RA, Ganote CE, & Jennings RB (1974)
The “no-reflow” phenomenon after
temporary coronary occlusion in the dog. The
Journal of clinical investigation 54 (6): 1496-
DOI:
https://doi.org/10.1172/JCI107898
Messner B, & Bernhard D (2014) Smoking and
cardiovascular disease: mechanisms of endothelial
dysfunction and early atherogenesis. Arteriosclerosis,
thrombosis, and vascular biology 34 (3): 509-515.
DOI:
https://doi.oig/10.1161/ATVBAHA113.300156
Mousa MJ, Al Saffar HS, & Al-Hindy H (2020) Low
Level Laser (Biophotomodulation) Therapy for
the Treatment of Diabetic Foot Ulcers with 532
nm KTP Laser Induces Wound Healing,
Fibroblast Proliferation and Over-expression of
TGF-|3. Systematic Reviews in Pharmacy 11 (6):
-403. DOI:
https://doi.Org/10.31838/srp.2020.6.63
Niccoli G, Burzotta F, Galiuto L, & Crea F
(2009) Myocardial no-reflow in humans.
Journal of the American College of
Cardiology 54 (4): 281-292. URL:
https://www jacc.org/doi/abs/10.1016/j jacc.
03.054
O’gara PT, Kushner FG, Ascheim DD, Casey Jr
DE, Chung MK et al. (2013) 2013
ACCF/AHA guideline for the management of
ST-elevation myocardial infarction: executive
summary: a report of the American College of
Cardiology Foundation/American Heart
Association Task Force on Practice
Guidelines. Circulation 127 (4): 529-555.
DOI:
https://doi.Org/l0.1161/CIR.ObO13e3182742
c84
Reffemann T, & Kloner RA (2004) Microvascular
alterations after temporary coronary artery
occlusion: the no-reflow phenomenon. Journal of
cardiovascular pharmacology and therapeutics 9
(3): 163-172. DOI:https://doi.oig/10.1177/107424840400900303
Shaker AK, Al-Saad R, Jasim R, & Al-Hindy HAAM (2020) Biochemical Significance of
Cystatin-C and High-Sensitive CRP in
Patients with Acute Coronary Syndrome; any
Clinical Correlation with Diagnosis and
Ejection Fraction. Systematic Reviews in
Pharmacy 11 (3): 301-308. DOI:
http://dx.doi.Org/10.5530/srp.2019.2.04
Sianos G, & Serruys PW (2011) Angiographic
thrombus burden classification in patients
with ST-segment elevation myocardial
infarction treated with percutaneous coronary
intervention. Journal of Invasive Cardiology
(10): 6B-14B. URL:
http://hdl.handle.net/1765/84854
Task Force Members, Steg PG, James SK, Atar
D, Badano LP et al. (2012) ESC Guidelines
for the management of acute myocardial
infarction in patients presenting with STsegment elevation: The Task Force on the
management of ST-segment elevation acute
myocardial infarction of the European Society
of Cardiology (ESC). European heart journal
(20): 2569-2619. DOI:
https://doi.org/10.1093/eurheartj/ehs215
Weaver WD, Simes RJ, Betriu A, Grines CL,
Zijlstra F et al. (1997) Comparison of primary
coronary angioplasty and intravenous
thrombolytic therapy for acute myocardial
infarction: a quantitative review. Jama 278
(23): 2093-2098. DOI:
https://doi.org/10.1001/jama.1997.03550230
Writing Committee Members, Levine GN, Bates
ER, Blankenship JC, Bailey SR et al. (2011)
ACCF/AHA/SCAI guideline for
percutaneous coronary intervention:
executive summary: a report of the American
College of Cardiology Foundation/American
Heart Association Task Force on Practice
Guidelines and the Society for Cardiovascular
Angiography and Interventions. Circulation
(23): 2574-2609. DOI:
https://doi.org/10.1161/CIR.0b013e31823a5
Yang L, Cong H, Lu Y, Chen X, & Liu Y (2020)
Prediction of no-reflow phenomenon in
patients treated with primary percutaneous
coronary intervention for ST-segment
elevation myocardial infarction. Medicine 99
(26). DOI:
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
